ADMA News and Press, ADMA Biologics Inc From 04/19/21

Shares of ADMA Biologics Inc (NASDAQ:ADMA) traded today at $1.56, breaking its 52-week low. This new low was reached on below average trading volume as 1.6 million shares traded hands, while the average 30-day volume is approximately 2.9 million shares. ADMA Biologics Inc is an end-to-en...

Poster Presentation Highlights the Unmet Patient Need and Medical Cost Burden Associated with Hepatitis B Infection Healthcare Costs Associated with HBV and HIV are Approximately at Parity; HBV Carries 50-100 Times Greater Transmission Risk Compared to HIV Pharmacoeconom...

ADMA Biologics recently reported a mixed Q4/2020 earnings with a slight miss on EPS and a slight beat on revenue. Consequently, ADMA has been under substantial selling pressure. The ongoing pandemic has disrupted the industry; however, ADMA was able to report record revenue and expect...

ADMA continues to execute and delivered another great quarter. ADMA has improved its guidance with respect to profitability and plasma center developments. Despite this, ADMA's ATM program has depressed the stock. For further details see: ADMA Biologics: Continuing To Ex...

ADMA Biologics, Inc. (ADMA) Q4 2020 Results Earnings Conference Call March 25, 2021, 04:30 PM ET Company Participants Skyler Bloom - Director, Investor Relations and Corporate Strategy Adam Grossman - Founder, President and Chief Executive Officer Brian Lenz - Executive Vice President and Chi...

Image source: The Motley Fool. ADMA Biologics Inc (NASDAQ: ADMA) Q4 2020 Earnings Call Mar 25, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: ADMA Biologics Inc (ADMA) Q4 2020 Earnings Call Transcript

ADMA Biologics (ADMA): Q4 GAAP EPS of -$0.20 misses by $0.02.Revenue of $13.96M (+15.9% Y/Y) beats by $0.11M.At December 31, 2020, ADMA had cash and cash equivalents of $55.9 million and accounts receivable of $13.2 million.Accelerated ADMA BioCenters Plasma Collection Network Expansion Guida...

Achieved Full Year 2020 Total Revenues of $42.2 Million, a 44% Increase Over Full Year 2019 Accelerated ADMA BioCenters Plasma Collection Network Expansion Guidance; Anticipates Having 10 or More Plasma Collection Centers in Operation by 2024 Management to Host Conferenc...

RAMSEY, N.J. and BOCA RATON, Fla., March 18, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that ...

A new study has found that patients with COVID-19 given convalescent plasma did not show a survival benefit compared to those on standard of care.The study, which has yet to be peer reviewed, found that there was no difference in 28-day mortality between the two groups.Results also showed tha...